10-20828531-G-T
Variant summary
Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP4_StrongBP6
The NM_006393.3(NEBL):c.1775C>A(p.Ala592Glu) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000204 in 1,561,152 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 17/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A592V) has been classified as Likely benign.
Frequency
Consequence
NM_006393.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -3 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NEBL | NM_006393.3 | c.1775C>A | p.Ala592Glu | missense_variant, splice_region_variant | 17/28 | ENST00000377122.9 | NP_006384.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NEBL | ENST00000377122.9 | c.1775C>A | p.Ala592Glu | missense_variant, splice_region_variant | 17/28 | 1 | NM_006393.3 | ENSP00000366326 |
Frequencies
GnomAD3 genomes AF: 0.000953 AC: 145AN: 152108Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000268 AC: 67AN: 249848Hom.: 1 AF XY: 0.000252 AC XY: 34AN XY: 135080
GnomAD4 exome AF: 0.000122 AC: 172AN: 1408926Hom.: 1 Cov.: 28 AF XY: 0.000115 AC XY: 81AN XY: 703974
GnomAD4 genome AF: 0.000959 AC: 146AN: 152226Hom.: 0 Cov.: 32 AF XY: 0.00103 AC XY: 77AN XY: 74422
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 04, 2024 | Originally reported in a female patient with neonatal DCM who also harbored a missense variant in the ACTN2 gene (PMID: 26321576); Subsequently reported in a 23-year-old female with possible arrhythmogenic right ventricular cardiomyopathy (ARVC) (PMID: 27194543); Mouse models harboring the p.(A592E) variant exhibited DCM and impaired cardiac function (PMID: 20951326, 23632046); In silico analysis supports that this missense variant does not alter protein structure/function; Variants in candidate genes are classified as variants of uncertain significance in accordance with ACMG guidelines (PMID: 25741868); This variant is associated with the following publications: (PMID: 23299917, 23632046, 25525159, 27186169, 27896284, 25987543, 27733623, 21430528, 33861145, 26321576, 27194543, 20951326, 34797172) - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 18, 2013 | The p.A592E variant (also known as c.1775C>A) is located in coding exon 17 of the NEBL gene. This alteration results from a C to A substitution at nucleotide position 1775, which is the second to last nucleotide position in exon 17. The alanine at codon 592 is replaced by glutamate, an amino acid with dissimilar properties. In one study, the p.A592E variant was detected in conjunction with a digenic mutation in ACTN2 in a patient diagnosed in the newborn period with dilated cardiomyopathy (DCM). The authors describe p.A592E transgenic mice (A592E-Tg), which displayed signs of DCM. By 6 months of age, the A592E-Tg mice displayed significantly decreased running distances compared to transgenic-wild type (WT-Tg) and non-transgenic mice (non-Tg) (p < 0.01). Significant fractional shortening was observed in A592E-Tg mice compared to non-TG and WT-Tg mice (p < 0.05). Significant dilatation of the left ventricle was also observed in A592E-Tg mice. In addition, Z-disk-associated proteins appeared to be downregulated and more disrupted in A592E-Tg hearts upon protein expression assays (Purevjav et al. 2010 JACC 56(18):1493-502).This variant was previously reported in the SNPDatabase as rs146275785. Based on data from the NHLBI Exome Sequencing Project (ESP), the A-allele has an overall frequency of approximately 0.13% (17/13004), having been observed in 0.36% (13/4406) of African American alleles, and in 0.01% (1/8598) of European American alleles studied. Based on data from the 1000 Genomes Project, the A-allele has an overall frequency of approximately 0.05% (1/2184). The highest observed frequency was 0.57% (1/176) of Yoruban West African chromosomes studied.Based on nucleotide alignment in available species, this nucleotide position is poorly conserved. Based on protein sequence alignment in available, this amino acid position is poorly conserved. Using the BDGP and ESEfinder splice site prediction tools, this alteration does not have any significant effect on the native acceptor splice site; however, direct evidence is unavailable. Based on the majority of available evidence to date, this variant is unlikely to be pathogenic. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence for this variant is conflicting at this time, the clinical significance remains unclear. - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 17, 2016 | p.Ala592Glu in exon 17 of NEBL: This variant is not expected to have clinical si gnificance because it has been identified in 0.3% (28/10104) of African chromoso mes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; d bSNP rs146275785). - |
NEBL-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 16, 2023 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Primary dilated cardiomyopathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 19, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at